SCHEMBL30294497

SCHEMBL30294497

Cc1cc(F)ccc1Nc1cccc(C(F)F)c1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 1/20 0.43
FABP3 P05413 4/20 0.40
FABP4 P15090 4/20 0.40
MKNK2 Q9HBH9 1/20 0.40
P2RY4 P51582 1/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
RECQL P46063 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GFER P55789 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PBRM1 Q86U86 1/20 0.38
CYP2C9 P11712 1/20 0.38
PIK3CA P42336 1/20 0.37
PIK3CG P48736 1/20 0.37
METAP2 P50579 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852780 1.00 MEN1 (0.43) MEN1KMT2AMAPK1FABP3FABP4
SCHEMBL30294439 0.84 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL22853099 0.84 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL22852851 0.84 PBRM1 (0.56) MEN1KMT2AMAPK1FABP3FABP4
SCHEMBL30294311 0.84 PBRM1 (0.56) MEN1KMT2AMAPK1FABP3FABP4
SCHEMBL22852801 0.84 FTO (0.48) MEN1KMT2AMAPK1FABP3FABP4
SCHEMBL30294752 0.84 FTO (0.48) MEN1KMT2AMAPK1FABP3FABP4
SCHEMBL22852844 0.80 TAS2R14 (0.49) MEN1KMT2AMAPK1FABP3FABP4
SCHEMBL30294602 0.80 TAS2R14 (0.49) MEN1KMT2AMAPK1FABP3FABP4
SCHEMBL22853005 0.78 P2RY4 (0.46) MEN1KMT2AMAPK1FABP3FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B MEN1 1826/4885KMT2A 2375/4885MAPK1 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.